{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:39:03Z","timestamp":1790707143170,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012688","name":"Universit\u00e4t Rostock","doi-asserted-by":"publisher","award":["889006"],"award-info":[{"award-number":["889006"]}],"id":[{"id":"10.13039\/501100012688","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The diagnosis of intensive care unit (ICU)-acquired weakness (ICUAW) and critical illness neuromyopathy (CINM) is frequently hampered in the clinical routine. We evaluated a novel panel of blood-based inflammatory, neuromuscular, and neurovascular biomarkers as an alternative diagnostic approach for ICUAW and CINM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients admitted to the ICU with a Sequential Organ Failure Assessment score of\u2009\u2265\u20098 on 3 consecutive days within the first 5 days as well as healthy controls were enrolled. The Medical Research Council Sum Score (MRCSS) was calculated, and motor and sensory electroneurography (ENG) for assessment of peripheral nerve function were performed at days 3 and 10. ICUAW was defined by an MRCSS\u2009&lt;\u200948 and CINM by pathological ENG alterations, both at day 10. Blood samples were taken at days 3, 10, and 17 for quantitative analysis of 18 different biomarkers (white blood cell count, C-reactive protein, procalcitonin, C-terminal agrin filament, fatty-acid-binding protein 3, growth and differentiation factor 15, syndecan 1, troponin I, interferon-\u03b3, tumor necrosis factor-\u03b1, interleukin-1\u03b1 [IL-1\u03b1], IL-1\u03b2, IL-4, IL-6, IL-8, IL-10, IL-13, and monocyte chemoattractant protein 1). Results of the biomarker analysis were categorized according to the ICUAW and CINM status. Clinical outcome was assessed after 3 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between October 2016 and December 2018, 38 critically ill patients, grouped into ICUAW (18 with and 20 without) and CINM (18 with and 17 without), as well as ten healthy volunteers were included. Biomarkers were significantly elevated in critically ill patients compared to healthy controls and correlated with disease severity and 3-month outcome parameters. However, none of the biomarkers enabled discrimination of patients with and without neuromuscular impairment, irrespective of applied classification.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Blood-based biomarkers are generally elevated in ICU patients but do not identify patients with ICUAW or CINM.<\/jats:p>\n            <jats:p>\n              <jats:italic>Trial registration<\/jats:italic>\n              <jats:bold>:<\/jats:bold> ClinicalTrials.gov identifier: NCT02706314.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12028-024-02050-x","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T21:01:31Z","timestamp":1720558891000},"page":"118-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Longitudinal Assessment of Blood-Based Inflammatory, Neuromuscular, and Neurovascular Biomarker Profiles in Intensive Care Unit\u2013Acquired Weakness: A Prospective Single-Center Cohort Study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-0892","authenticated-orcid":false,"given":"Felix","family":"Klawitter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Laukien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar-C.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Rahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Porath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Danckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Bajorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Patejdl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Ehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"4","key":"2050_CR1","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00134-020-05944-4","volume":"46","author":"I Vanhorebeek","year":"2020","unstructured":"Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired weakness. Intensive Care Med. 2020;46(4):637\u201353.","journal-title":"Intensive Care Med"},{"key":"2050_CR2","doi-asserted-by":"crossref","unstructured":"Latronico N, Rasulo FA, Eikermann M, Piva S. Illness weakness, polyneuropathy and myopathy: diagnosis, treatment, and long-term outcomes. Crit Care. 2023;27(1):439. Erratum in: Crit Care. 2023;27(1):469.","DOI":"10.1186\/s13054-023-04676-3"},{"issue":"8","key":"2050_CR3","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s00101-022-01089-9","volume":"71","author":"F Klawitter","year":"2022","unstructured":"Klawitter F, Schaller SJ, S\u00f6hle M, Reuter DA, Ehler J. Intensive care unit-acquired weakness: a nationwide survey on diagnostics, monitoring and treatment strategies on German intensive care units. Anaesthesiologie. 2022;71(8):618\u201325.","journal-title":"Anaesthesiologie."},{"issue":"1","key":"2050_CR4","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/s13054-020-03282-x","volume":"24","author":"Z Turan","year":"2020","unstructured":"Turan Z, Topaloglu M, Ozyemisci TO. Medical Research Council-sumscore: a tool for evaluating muscle weakness in patients with post-intensive care syndrome. Crit Care. 2020;24(1):562.","journal-title":"Crit Care"},{"key":"2050_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.physio.2021.01.002","volume":"112","author":"Y Wu","year":"2021","unstructured":"Wu Y, Zhang Z, Jiang B, Wang G, Wei H, Li B, et al. Current practice and barriers to ICU-acquired weakness assessment: a cross-sectional survey. Physiotherapy. 2021;112:135\u201342.","journal-title":"Physiotherapy"},{"issue":"8","key":"2050_CR6","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3390\/medicina58081068","volume":"58","author":"F Klawitter","year":"2022","unstructured":"Klawitter F, Oppitz MC, Goettel N, Berger MM, Hodgson C, Weber-Carstens S, et al. A global survey on diagnostic, therapeutic and preventive strategies in intensive care unit-acquired weakness. Medicina (Kaunas). 2022;58(8):1068.","journal-title":"Medicina (Kaunas)"},{"issue":"8","key":"2050_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00101-023-01300-5","volume":"72","author":"F Klawitter","year":"2023","unstructured":"Klawitter F, Walter U, Axer H, Ehler J. Intensive care unit-acquired weakness-diagnostic value of neuromuscular ultrasound. Anaesthesiologie. 2023;72(8):543\u201354.","journal-title":"Anaesthesiologie."},{"issue":"12","key":"2050_CR8","doi-asserted-by":"publisher","first-page":"10335","DOI":"10.3390\/ijms241210335","volume":"24","author":"J Ruhnau","year":"2023","unstructured":"Ruhnau J, M\u00fcller J, Nowak S, Strack S, Sperlich D, Pohl A, et al. Serum biomarkers of a pro-neuroinflammatory state may define the pre-operative risk for postoperative delirium in spine surgery. Int J Mol Sci. 2023;24(12):10335.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2050_CR9","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5507\/bp.2019.043","volume":"163","author":"T Saller","year":"2019","unstructured":"Saller T, Petzold A, Zetterberg H, Kuhle J, Chappell D, von Dossow V, et al. A case series on the value of tau and neurofilament protein levels to predict and detect delirium in cardiac surgery patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2019;163(3):241\u20136.","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"1","key":"2050_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13054-023-04497-4","volume":"27","author":"B Bircak-Kuchtova","year":"2023","unstructured":"Bircak-Kuchtova B, Chung HY, Wickel J, Ehler J, Geis C. Neurofilament light chains to assess sepsis-associated encephalopathy: are we on the track toward clinical implementation? Crit Care. 2023;27(1):214.","journal-title":"Crit Care"},{"issue":"1","key":"2050_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2044-5040-2-2","volume":"2","author":"J De Larichaudy","year":"2012","unstructured":"De Larichaudy J, Zufferli A, Serra F, Isidori AM, Naro F, Dessalle K, et al. TNF-\u03b1- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skelet Muscle. 2012;2(1):2.","journal-title":"Skelet Muscle"},{"issue":"4","key":"2050_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1164\/rccm.2202005","volume":"166","author":"MB Reid","year":"2002","unstructured":"Reid MB, L\u00e4nnergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002;166(4):479\u201384.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2050_CR13","doi-asserted-by":"publisher","first-page":"C825","DOI":"10.1152\/ajpcell.00173.2012","volume":"303","author":"R Wondergem","year":"2012","unstructured":"Wondergem R, Graves BM, Li C, Williams DL. Lipopolysaccharide prolongs action potential duration in HL-1 mouse cardiomyocytes. Am J Physiol Cell Physiol. 2012;303(8):C825\u201333.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"2050_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/00024382-199904000-00002","volume":"11","author":"RN Cooney","year":"1999","unstructured":"Cooney RN, Maish GO 3rd, Gilpin T, Shumate ML, Lang CH, Vary TC. Mechanism of IL-1 induced inhibition of protein synthesis in skeletal muscle. Shock. 1999;11(4):235\u201341.","journal-title":"Shock"},{"issue":"1","key":"2050_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0304-3835(98)00216-X","volume":"133","author":"M Llovera","year":"1998","unstructured":"Llovera M, Carb\u00f3 N, L\u00f3pez-Soriano J, Garc\u00eda-Mart\u00ednez C, Busquets S, Alvarez B, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 1998;133(1):83\u20137.","journal-title":"Cancer Lett"},{"issue":"5","key":"2050_CR16","doi-asserted-by":"publisher","first-page":"C1183","DOI":"10.1152\/ajpcell.00568.2007","volume":"294","author":"M Cheng","year":"2008","unstructured":"Cheng M, Nguyen MH, Fantuzzi G, Koh TJ. Endogenous interferon-gamma is required for efficient skeletal muscle regeneration. Am J Physiol Cell Physiol. 2008;294(5):C1183\u201391.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2050_CR17","doi-asserted-by":"crossref","unstructured":"Piotti A, Novelli D, Meessen JM, Ferlicca D, Coppolecchia S, Marino A, et al.; ALBIOS Investigators. Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS. Crit Care. 2021;25(1):113.","DOI":"10.1186\/s13054-021-03545-1"},{"issue":"2","key":"2050_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1017\/cjn.2018.390","volume":"46","author":"R Patejdl","year":"2019","unstructured":"Patejdl R, Walter U, Rosener S, Sauer M, Reuter DA, Ehler J. Muscular ultrasound, syndecan-1 and procalcitonin serum levels to assess intensive care unit-acquired weakness. Can J Neurol Sci. 2019;46(2):234\u201342.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"2050_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13054-015-0993-7","volume":"19","author":"G Hermans","year":"2015","unstructured":"Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19(1):274.","journal-title":"Crit Care"},{"issue":"6","key":"2050_CR20","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/diagnostics12061378","volume":"12","author":"F Klawitter","year":"2022","unstructured":"Klawitter F, Walter U, Patejdl R, Endler J, Reuter DA, Ehler J. Sonographic evaluation of muscle echogenicity for the detection of intensive care unit-acquired weakness: a pilot single-center prospective cohort study. Diagnostics (Basel). 2022;12(6):1378.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"2050_CR21","doi-asserted-by":"publisher","first-page":"24249","DOI":"10.1038\/s41598-021-03711-z","volume":"11","author":"R Patejdl","year":"2021","unstructured":"Patejdl R, Klawitter F, Walter U, Zanaty K, Schwandner F, Sellmann T, et al. A novel ex vivo model for critical illness neuromyopathy using freshly resected human colon smooth muscle. Sci Rep. 2021;11(1):24249.","journal-title":"Sci Rep"},{"key":"2050_CR22","doi-asserted-by":"crossref","unstructured":"De Jonghe B, Bastuji-Garin S, Durand MC, Malissin I, Rodrigues P, Cerf C, et al.; Groupe de R\u00e9flexion et d\u2019Etude des Neuromyopathies en R\u00e9animation. Respiratory weakness is associated with limb weakness and delayed weaning in critical illness. Crit Care Med. 2007;35(9):2007\u201315.","DOI":"10.1097\/01.ccm.0000281450.01881.d8"},{"issue":"11","key":"2050_CR23","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg RP, van der Mech\u00e9 FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve. 1991;14(11):1103\u20139.","journal-title":"Muscle Nerve"},{"issue":"10 Suppl","key":"2050_CR24","doi-asserted-by":"publisher","first-page":"S299","DOI":"10.1097\/CCM.0b013e3181b6ef67","volume":"37","author":"RD Stevens","year":"2009","unstructured":"Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(10 Suppl):S299-308.","journal-title":"Crit Care Med"},{"issue":"3","key":"2050_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/CCM.0000000000000030","volume":"42","author":"G Vanpee","year":"2014","unstructured":"Vanpee G, Hermans G, Segers J, Gosselink R. Assessment of limb muscle strength in critically ill patients: a systematic review. Crit Care Med. 2014;42(3):701\u201311.","journal-title":"Crit Care Med"},{"issue":"1","key":"2050_CR26","doi-asserted-by":"publisher","first-page":"R18","DOI":"10.1186\/cc13699","volume":"18","author":"L Wieske","year":"2014","unstructured":"Wieske L, Witteveen E, Petzold A, Verhamme C, Schultz MJ, van Schaik IN, et al. Neurofilaments as a plasma biomarker for ICU-acquired weakness: an observational pilot study. Crit Care. 2014;18(1):R18.","journal-title":"Crit Care"},{"issue":"15","key":"2050_CR27","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.3390\/ijms23158396","volume":"23","author":"M Kanova","year":"2022","unstructured":"Kanova M, Kohout P. Molecular mechanisms underlying intensive care unit-acquired weakness and sarcopenia. Int J Mol Sci. 2022;23(15):8396.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2050_CR28","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.3390\/biomedicines10092283","volume":"10","author":"B Li","year":"2022","unstructured":"Li B, Syed MH, Khan H, Singh KK, Qadura M. The role of fatty acid binding protein 3 in cardiovascular diseases. Biomedicines. 2022;10(9):2283.","journal-title":"Biomedicines"},{"issue":"2","key":"2050_CR29","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1756-185X.12838","volume":"20","author":"L Zhang","year":"2017","unstructured":"Zhang L, Zhou H, Peng Q, Jiang W, Qiao W, Wang G. Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. Int J Rheum Dis. 2017;20(2):252\u201360.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2050_CR30","doi-asserted-by":"publisher","first-page":"8632","DOI":"10.1038\/s41598-021-87974-6","volume":"11","author":"R Qaisar","year":"2021","unstructured":"Qaisar R, Karim A, Muhammad T, Shah I, Khan J. Prediction of sarcopenia using a battery of circulating biomarkers. Sci Rep. 2021;11(1):8632.","journal-title":"Sci Rep"},{"issue":"1","key":"2050_CR31","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1038\/s41467-020-19501-6","volume":"11","author":"SM Lee","year":"2020","unstructured":"Lee SM, Lee SH, Jung Y, Lee Y, Yoon JH, Choi JY, et al. FABP3-mediated membrane lipid saturation alters fluidity and induces ER stress in skeletal muscle with aging. Nat Commun. 2020;11(1):5661.","journal-title":"Nat Commun"},{"issue":"3","key":"2050_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.102921","volume":"299","author":"HC Nguyen","year":"2023","unstructured":"Nguyen HC, Bu S, Nikfarjam S, Rasheed B, Michels DC, Singh A, et al. Loss of fatty acid binding protein 3 ameliorates lipopolysaccharide-induced inflammation and endothelial dysfunction. J Biol Chem. 2023;299(3): 102921.","journal-title":"J Biol Chem"},{"issue":"1","key":"2050_CR33","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1038\/s41598-022-10208-w","volume":"12","author":"PM Kowalewska","year":"2022","unstructured":"Kowalewska PM, Kowalewski JE, Milkovich SL, Sov\u00e9 RJ, Wang L, Whitehead SN, et al. Spectroscopy detects skeletal muscle microvascular dysfunction during onset of sepsis in a rat fecal peritonitis model. Sci Rep. 2022;12(1):6339.","journal-title":"Sci Rep"},{"issue":"2","key":"2050_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/jcsm.13189","volume":"14","author":"E Monti","year":"2023","unstructured":"Monti E, Sarto F, Sartori R, Zanchettin G, L\u00f6fler S, Kern H, et al. C-terminal agrin fragment as a biomarker of muscle wasting and weakness: a narrative review. J Cachexia Sarcopenia Muscle. 2023;14(2):730\u201344.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"2050_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/jcsm.12068","volume":"7","author":"N Scherbakov","year":"2016","unstructured":"Scherbakov N, Knops M, Ebner N, Valentova M, Sandek A, Grittner U, et al. Evaluation of C-terminal agrin fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation. J Cachexia Sarcopenia Muscle. 2016;7(1):60\u20137.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"2050_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/thoraxjnl-2014-206225","volume":"70","author":"SA Bloch","year":"2015","unstructured":"Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, et al. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. Thorax. 2015;70(3):219\u201328.","journal-title":"Thorax"},{"key":"2050_CR37","doi-asserted-by":"publisher","first-page":"3630568","DOI":"10.1155\/2020\/3630568","volume":"2020","author":"Y Xie","year":"2020","unstructured":"Xie Y, Liu S, Zheng H, Cao L, Liu K, Li X. Utility of plasma GDF-15 for diagnosis and prognosis assessment of ICU-acquired weakness in mechanically ventilated patients: prospective observational study. BioMed Res Int. 2020;2020:3630568.","journal-title":"BioMed Res Int"},{"issue":"2","key":"2050_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/1099800414532709","volume":"17","author":"C Winkelman","year":"2015","unstructured":"Winkelman C, Johnson KD, Gordon N. Associations between muscle-related cytokines and selected patient outcomes in the ICU. Biol Res Nurs. 2015;17(2):125\u201334.","journal-title":"Biol Res Nurs"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-02050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-024-02050-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-02050-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:57:50Z","timestamp":1739462270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-024-02050-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1007\/s12028-024-02050-x","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UW has received speaker honoraria and travel grants from Bristol-Myers Squibb, Boehringer Ingelheim Pharma, Daiichi-Sankyo, Ipsen Pharma, Merz Pharmaceuticals, and Pfizer Pharma and an unrestricted research grant from Merz Pharmaceuticals independent from this study. He serves as joint editor-in-chief of the European Journal of Ultrasound (Thieme, Stuttgart, Germany). JE received financial support for attending study meetings from B. Braun Melsungen AG independent from this study. FK, FL, D-CF, AR, KP, LD, RP, and RB have nothing to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and was approved by the local ethics committee of the University of Rostock (ethics identifier AS 2016\u20130016). Written informed consent for participation was given by volunteers, patients, or a legal representative before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval\/Informed Consent"}},{"value":"ClinicalTrials.gov identifier: NCT02706314.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Registration"}}]}}